Clinical Research Directory
Browse clinical research sites, groups, and studies.
Artificial Intelligence (AI)-Assisted Risk-based Prostate Cancer Detection
Sponsor: Chinese University of Hong Kong
Summary
This is a prospective clinical study recruiting 510 men at risk of PCa to undergo urine, blood, AI-assisted ultrasound and AI-assisted MRI investigations to stratify risk of clinically significant PCa (csPCa). (sample size calculation in section 5)
Official title: Artificial Intelligence (AI)-Assisted Risk-based Prostate Cancer Detection: A Synergy of Novel Biomarkers, Advanced Imaging, and Robotic-assisted Diagnosis
Key Details
Gender
MALE
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
510
Start Date
2023-08-01
Completion Date
2026-10-30
Last Updated
2025-05-20
Healthy Volunteers
Yes
Conditions
Interventions
Diagnostic test for prostate cancer
All recruited patients will undergo investigations including urine for spermine, blood for miRNA, TRUS, and MRI prostate. Patients with high suspicion of Clinically significant prostate cancer in any one step (urine, blood, ultrasound, OR MRI) will be offered an image-guided prostate biopsy.
Locations (1)
Prince of Wales Hospital, Chinese University of Hong Kong
Hong Kong, Hong Kong